Equities

Indivior PLC

INDV:LSE

Indivior PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)743.50
  • Today's Change30.00 / 4.20%
  • Shares traded569.82k
  • 1 Year change-57.76%
  • Beta-0.1273
Data delayed at least 20 minutes, as of Sep 27 2024 16:52 BST.
More ▼

Profile data is unavailable for this security.

About the company

Indivior PLC is a pharmaceutical company. The Company is engaged in developing medicines to treat substance use disorders (SUD), serious mental illnesses, and opioid overdose. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder, and co-morbidities, including schizophrenia. Its core products include SUBLOCADE (buprenorphine extended release) monthly injection; SUBOXONE Film (buprenorphine and naloxone sublingual film); SUBOXONE Tablet (buprenorphine and naloxone sublingual tablets), and SUBUTEX Tablet (buprenorphine sublingual tablets). Its products for the treatment of opioid disorders (OUD) are OPVEE (nalmefene) nasal spray for opioid overdose reversal, and PERSERIS (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults in the United States. Its portfolio of products is available in 37 countries.

  • Revenue in GBP (TTM)857.70m
  • Net income in GBP-105.44m
  • Incorporated2014
  • Employees1.05k
  • Location
    Indivior PLC10710 Midlothian TurnpikeSuite 125, North ChesterfieldCHESTERFIELD 23235United StatesUSA
  • Phone+0 (804) 379-1090
  • Websitehttps://www.indivior.com/en
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Zhejiang Hisun Pharmaceutical Co., Ltd.1.02bn-8.25m900.13m8.06k900.13m8.06k
Collegium Pharmaceutical Inc431.16m74.69m903.22m197.00903.22m197.00
Calliditas Therapeutics AB118.67m-35.60m908.26m222.00908.26m222.00
ANI Pharmaceuticals Inc402.97m17.16m920.01m642.00920.01m642.00
Kissei Pharmaceutical Co Ltd407.14m63.10m920.15m1.78k920.15m1.78k
Innoviva Inc247.11m108.73m926.66m112.00926.66m112.00
Indivior PLC857.70m-105.44m933.40m1.05k933.40m1.05k
Aurisco Pharmaceutical Co Ltd153.63m40.75m945.56m1.52k945.56m1.52k
Tarsus Pharmaceuticals Inc62.34m-112.21m946.03m244.00946.03m244.00
Changchun BCHT Biotechnology Co200.86m56.23m961.42m1.24k961.42m1.24k
Polypeptide Group AG273.17m-23.84m961.61m1.28k961.61m1.28k
KPC Pharmaceuticals Inc798.44m48.07m962.44m5.05k962.44m5.05k
KAKEN PHARMACEUTICAL CO., LTD.379.37m38.22m968.75m1.14k968.75m1.14k
Data as of Sep 27 2024. Currency figures normalised to Indivior PLC's reporting currency: UK Pound GBX

Institutional shareholders

51.40%Per cent of shares held by top holders
HolderShares% Held
Two Seas Capital LPas of 20 Jun 202413.26m9.98%
Morgan Stanley & Co. International Plcas of 31 Dec 20239.74m7.33%
Oaktree Capital Management LPas of 09 Jul 20249.38m7.06%
Soci�t� G�n�rale Gestion SAas of 02 Jul 20246.77m5.09%
Scopia Capital Management LPas of 19 Mar 20246.29m4.73%
Fidelity Management & Research Co. LLCas of 31 Jul 20245.13m3.87%
Barclays Capital Securities Ltd.as of 30 Jun 20244.64m3.49%
Madison Avenue Partners LPas of 14 Nov 20234.63m3.48%
The Vanguard Group, Inc.as of 31 Aug 20244.59m3.45%
BlackRock Investment Management (UK) Ltd.as of 31 Aug 20243.87m2.91%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.